Navigation Links
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Date:3/10/2009

al sleep time (p<0.001), decreased total time awake (p<0.001) and improved sleep efficiency (calculated by the proportion of the time spent sleeping while in bed, p<0.001).

Intra-Cellular Therapies believes that ITI-007 promotes natural, restorative sleep. In particular, ITI-007 did not cause rebound insomnia during early morning hours and did not suppress rapid eye movement (REM) sleep as some hypnotic agents do. ITI-007 significantly and dose-dependently increased the percent of SWS early in the night (p=0.022 for the first quarter of the night, p=0.029 for the second quarter of the night). Late in the night, towards morning, ITI-007 increased the percent of Stage 2 sleep (p=0.048 for the third quarter of the night, p=0.004 for the fourth quarter of the night). ITI-007 did not affect total duration of REM sleep (p=0.124) and ITI-007 did not affect latency to the first episode of REM (p=0.143). As predicted by its mechanism, ITI-007 did not affect latency to persistent sleep (p=0.455). Overall, the increases in SWS and Stage 2 sleep came at the expense of decreased percent time spent awake or drowsy (Stage 1 sleep, p<0.001). This was especially reflected by the ability of ITI-007 to decrease percent time spent awake or drowsy in the fourth quarter of the night compared to placebo (p=0.002), a time when other hypnotics tend to cause rebound increases in early morning wakefulness.

PHASE II RESULTS FOR ITI-007

                                                                  Dose-
                                                                Response
                                                                  Trend
    Polysomnography                                             Analysis
    Outcome Measure      Mean Change from Baseline (min)         p-value
                                             ITI-007
                       Placebo      1 mg      5 mg     10 mg

    SWS  
'/>"/>
SOURCE Intra-Cellular Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
3. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
4. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
5. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
6. Old and new therapies combine to tackle atherosclerosis
7. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
8. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
9. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
10. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Currently ... Sartorius, A & D Weighing, Rice Lake, and ... Semi-Micro Balance . The Sartorius CPA Semi-Micro Balance ... affordable high-quality, precise, and user-friendly laboratory balance. , ... laboratory equipment, their laboratory balances are well known ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 According ... Market by Service Type (Consulting, Integration, Deployment & ... by Deployment Model (Public, Private, Others (Hybrid & ... MarketsandMarkets, defines and segments the Cloud Professional Services ... and forecasting of revenues. It also identifies the ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
Breaking Biology Technology:Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... has announced the formation of a Medical Advisory Council ... (MiCK) assay for apoptosis , a new assay designed ... patients. DiaTech has introduced this technology for individual patient ... companies in validating new drugs that may be more ...
... 2011  Rhythm announced today that Lex Van der Ploeg, ... Dr. Van der Ploeg brings to Rhythm more than ... diseases, and other therapeutic areas. "Lex has ... metabolic pathways we are targeting with our ghrelin and ...
... mystery of prematurely dead cell phone and laptop batteries may ... energy grid according to Drexel researcher Dr. Yury Gogotsi. In ... Science , Gogotsi, who is the head of the ... of performance measurement for energy storage devices that are as ...
Cached Biology Technology:DiaTech Life Sciences Announces Medical Advisory Board 2DiaTech Life Sciences Announces Medical Advisory Board 3Rhythm Names Lex Van der Ploeg Chief Scientific Officer 2Drexel expert: Efficiency metrics for energy storage devices need standardization 2
(Date:10/25/2014)... , Oct. 22, 2014 This report covers ... relatively new space in heavy pursuit of research due ... to miRNAs compared to other RNA components. miRNA,s non-coding ... a novel candidate for use as a biomarker for ... miRNA-based microarrays and diagnostics for the advancement in therapeutic ...
(Date:10/22/2014)... , Oct. 20, 2014 The Nano-Bio ... States Air Force Research Laboratory (AFRL), has chosen a ... (AzCIM) at the University of Arizona College of Medicine ... funding.  The AzCIM project,s goal is to assess different ... collect different volumes of sweat under a variety of ...
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
Breaking Biology News(10 mins):MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Researchers find why depression and aging linked to increased disease risk 2
... from an observational study by researchers at the University ... 65 and 80 years of age who received treatment ... than men who did not receive treatment. The study ... the Journal of the American Medical Association. , Thanks ...
... possible new cancer drug suggests that it may prove ... chemotherapeutic drugs. , Dr David Huang, Dr Andrew Roberts, ... research divisions have been assessing the potential of a ... company, Abbott. , Under normal circumstances, human ...
... to light is missing in humans, researchers have discovered. , ... amphibians have two versions of this photoreceptor, mammals, including humans, ... Public Library of Science journal PLoS Biology ?reveal how our ... other vertebrates and fits with the suggestion that early mammals ...
Cached Biology News:Older men treated for early prostate cancer live longer than those who are not 2Hope for a more effective and less toxic cancer drug 2Does missing gene point to nocturnal existence for early mammals? 2
Reacts with the 80 kDa fragment of the M-chain of human merosin....
ICAD / DFF45 (NT) Affinity Purified Polyclonal Antibody...
... polyclonal to ZFP91 ( Abpromise ... Antigen: Synthetic peptide derived ... human ZFP91. (Note: the amino ... Entrez Gene ID: ...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
Biology Products: